Skip directly to content

Research Toward a Cure Trials

Addthis

A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full clinicaltrials.gov entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s). It's important to appreciate that at the current time, none of these studies is expected to produce a cure for HIV infection—they represent research working toward that goal. Table 3 contains completed studies, with links to published or presented results where available. Changes from the previous update are highlighted in yellow. Additional information on current approaches in HIV cure research can be found in TAG's annual pipeline report and cure research fact sheet. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org.

July 18, 2016

Table 1. Current Clinical Trials

Trial

Trial Registry Identifier(s)

Manufacturer/
Sponsor(s)

Phase

Estimated Study Completion Date

ADOPTIVE IMMUNOTHERAPY

Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion

NCT02231281

Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University

Phase III

December 2016

Reconstitution of HIV-specific immunity against HIV

NCT02563509

Guangzhou 8th People's Hospital

Phase I/II

December 2016

HXTC: HIV 1 antigen expanded specific T cell therapy

NCT02208167

University of North Carolina, Chapel Hill

Phase I

September 2018

ANTIBODIES

VRC01 (broadly neutralizing monoclonal antibody)

NCT02664415
(not yet open for enrollment)

National Institute of Allergy and Infectious Diseases (NIAID)

Phase II

September 2016

3BNC117 (broadly neutralizing monoclonal antibody)

NCT02446847
(closed to enrollment)

Rockefeller University

Phase I/II

March 2018

3BNC117

NCT02588586

Rockefeller University

Phase I/II

March 2018

10-1074 (broadly neutralizing monoclonal antibody)

NCT02511990

Rockefeller University

Phase I

July 2017

3BNC117 + 10-1074

NCT02825797

Rockefeller University

Phase I

June 2018

vedolizumab (anti-αβ integrin antibody)

NCT02788175
(not yet open for enrollment)

NIAID

Phase I

May 2020

VRC01 in acute HIV infection (broadly neutralizing monoclonal antibody)

NCT02591420
(not yet open for enrollment)

NIAID

Phase I

December 2016

VRC01

NCT02471326
(closed to enrollment)

NIAID

Phase I

June 2018

VRC01

NCT02411539
(closed to enrollment)

NIAID

Phase I

November 2016

CHERUB 001
Intravenous immunoglobulin in primary HIV infection

No clinicaltrials.gov entry

CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC)

N/A

N/A

ANTI-FIBROTIC

losartan

NCT01852942

University of Minnesota

Phase II

July 2018

telmisartan

NCT02170246

Yale University

Phase I

February 2019

ANTI-INFLAMMATORY

canakinumab (IL-1β inhibitor)

NCT02272946

University of California, San Francisco

Phase II

June 2017

CC-11050 (phosphodiesterase-4 inhibitor)

NCT02652546

NIAID

Phase I

October 2017

metformin

NCT02659306
(not yet open for enrollment)

McGill University Health Center

Phase I

October 2017

ANTIRETROVIRAL THERAPY

HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen

NCT02513147
(closed to enrollment)

Hospital Universitari Vall d'Hebron Research Institute

Phase IV

November 2016

ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS

emtricitabine + rilpivirine + tenofovir

NCT01777997
(closed to enrollment)

AIDS Clinical Trials Group/NIAID

Phase IV

May 2017

COMBINATIONS                                                                                                   

Perturbing of HIV reservoir with immune stimulation: Fluarix, Pneumovax vaccines

NCT02707692
(not yet open for enrollment)

University of California, San Diego

Not listed

January 2021

panobinostat + pegylated interferon-alpha2a

NCT02471430

Massachusetts General Hospital

Phase II

February 2020

Research In Viral Eradication of HIV Reservoirs (RIVER): ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat

NCT02336074
UK CPMS18010

Imperial College London

 

Phase II

July 2018

SB-728mR-T (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide

NCT02225665
(closed to enrollment)

Sangamo BioSciences

Phase I/II

June 2018

SB-728-T + cyclophosphamide

NCT01543152
(closed to enrollment)

Sangamo BioSciences

Phase I/II

September 2016

AGS-004 + vorinostat

NCT02707900
(not yet open for enrollment)

NIAID

Phase I

December 2019

DCV3 (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon

NCT02767193
(not yet open for enrollment)

Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica

Phase I

June 2018

MVA.HIVconsv + romidepsin

NCT02616874

IrsiCaixa

Phase I

October 2017

SB-728mR-T + cyclophosphamide

NCT02388594

University of Pennsylvania

Phase I

March 2017

CD4-ZETA gene-modified T cells +/- interleukin-2 (IL-2)

NCT01013415
(closed to enrollment)

University of Pennsylvania

Phase I

June 2016

GENE THERAPIES

Cal-1: Dual anti-HIV gene transfer construct

ACTRN12615000763549

Calimmune

Phase I/II

N/A

Cal-1: Dual anti-HIV gene transfer construct

NCT01734850
NCT02390297 (long term safety phase)

Calimmune

Phase I/II

June 2015
January 2032

VRX496 (gene-modified autologous CD4 T cells)

NCT00295477
(closed to enrollment)

University of Pennsylvania

Phase I/II

December 2020

SB-728mR-HSPC (autologous hematopoietic stem/progenitor cells genetically modified at the CCR5 gene)

NCT02500849

City of Hope Medical Center

Phase I

July 2018

MazF-T (redirected MazF-CD4 autologous T cells)

NCT01787994
(closed to enrollment)

Takara Bio/University of Pennsylvania

Phase I

December 2016

GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS

Gene therapy in treating patients with HIV-related lymphoma receiving stem cell transplant

NCT02797470

AIDS Malignancy Consortium

Phase I/II

September 2019

High-dose chemotherapy with transplantation of gene-modified stem cells for high-risk AIDS-related lymphoma

NCT00858793
(suspended)

Universitätsklinikum Hamburg-Eppendorf

Phase I/II

October 2017

HIV-resistant gene modified stem cells and chemotherapy in treating patients with lymphoma and HIV infection

NCT02343666

Fred Hutchinson Cancer Research Center

Phase I

August 2020

Gene-modified HIV-protected stem cell transplant in treating patients with HIV-associated lymphoma

NCT02378922

Fred Hutchinson Cancer Research Center

Phase I

June 2019

Gene therapy and combination chemotherapy in treating patients with AIDS-related Non-Hodgkin Lymphoma

NCT02337985

City of Hope Medical Center

Not listed

June 2031

Busulfan and gene therapy after frontline chemotherapy in patients with AIDS-related non-Hodgkin’s lymphoma

NCT01961063
 

City of Hope Medical Center

Not listed

October 2030

Gene therapy-treated stem cells in patients undergoing stem cell transplant for intermediate-grade or high-grade AIDS-related lymphoma

NCT00569985
(closed to enrollment)

City of Hope Medical Center

Not listed

December 2015

IMMUNE CHECKPOINT INHIBITORS

nivolumab (anti-PD-1 antibody) + ipilimumab (ant-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors

NCT02408861

National Cancer Institute (NCI)

Phase I

December 2020

pembrolizumab (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms

NCT02595866

National Cancer Institute (NCI)

Phase I

April 2018

JANUS KINASE INHIBITORS

ruxolitinib

NCT02475655

NIAID

Phase II

October 2016

LATENCY-REVERSING AGENTS

MGN1703 toll-like receptor 9 (TLR-9) agonist

NCT02443935
(enrolling by invitation only)

University of Aarhus

Phase Ib/IIa

January 2017

Chidamide (HDAC inhibitor)

NCT02513901

Tang-Du Hospital

Phase I/II

December 2015

Poly-ICLC (TLR-3 agonist)

NCT02071095
(closed to enrollment)

Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc.

Phase I/II

June 2017

romidepsin (HDAC inhibitor)

NCT01933594

AIDS Clinical Trials Group/NIAID/Gilead

Phase I/II

January 2015

GS-9620 (TLR-7 agonist)

Not entered in clinicaltrials.gov

Gilead Sciences

Phase Ib

N/A

ALT-803 (recombinant human super agonist interleukin-15 complex)

NCT02191098

University of Minnesota - Clinical and Translational Science Institute

Phase I

June 2016

Kansui (traditional Chinese medicine containing ingenols)

NCT02531295
(not yet open for enrollment)

UCSF

Phase I

September 2016

mTOR INHIBITORS

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant

NCT02429869

UCSF

Phase IV

June 2017

Sirolimus

NCT02440789

ACTG

Phase I/II

December 2016

STEM CELL TRANSPLANTATION

BMT CTN 0903
Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection

NCT01410344
(closed to enrollment)

National Heart, Lung, and Blood Institute (NHLBI)/National Cancer Institute (NCI)/
Blood and Marrow Transplant Clinical Trials Network

Phase II

November 2015

Immune response after stem cell transplant in HIV-positive patients with hematologic cancer

NCT00968630

Fred Hutchinson Cancer Research Center

Phase II

September 2016

IMPAACT P1107
Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease

NCT02140944

IMPAACT/NIAID/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

N/A

N/A

THERAPEUTIC VACCINES

GTU-multiHIV + LIPO-5 (DNA + lipopeptide vaccines)

NCT01492985
(closed to enrollment)

French National Institute for Health and Medical Research/French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)

Phase II

October 2017

VAC-3S (peptide-based vaccine)

NCT02041247
(closed to enrollment)

InnaVirVax

Phase II

November 2016

VAC-3S

NCT02390466
(closed to enrollment)

InnaVirVax

Phase I/IIa

April 2017

GTU®-MultiHIV B Clade Vaccine

NCT02457689

Imperial College London

Phase I/II

February 2017

AGS-004

NCT02042248

University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH)

Phase I/II

December 2016

Tat Oyi (protein-based vaccine)

NCT01793818
(closed to enrollment)

Biosantech

Phase I/II

March 2016

THV01 (lentiviral vector-based therapeutic vaccine)

NCT02054286
(closed to enrollment)

Theravectys S.A.

Phase I/II

March 2019

Recombinant adenovirus type 5 vaccine

NCT02762045

Centers for Disease Control and Prevention, China

Phase I

December 2017

iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)

NCT02413645

Biomedical Research Institute August Pi i Sunyer (IDIBAPS)

Phase I

October 2016

HIVAX (lentiviral vector-based therapeutic vaccine)

NCT01428596

GeneCure Biotechnologies

Phase I

December 2015

MAG-pDNA + rVSVIN HIV-1 Gag (DNA + viral vector vaccines)

NCT01859325
(closed to enrollment)

NIAID/Profectus Biosciences, Inc.

Phase I

November 2016

TRADITIONAL CHINESE MEDICINE

Triptolide wilfordii

NCT02219672

Peking Union Medical College

Phase III

July 2017

TREATMENT INTENSIFICATION/EARLY TREATMENT

LEOPARD: Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

NCT02431975

Columbia University

Not listed

July 2020

New Era Study: Treatment with multidrug class (MDC) HAART

NCT00908544
(closed to enrollment)

MUC Research GmbH

Not listed

November 2019

Antiretroviral regime for viral eradication in newborns

NCT02712801
(not yet open for enrollment)

National Center for Women and Children's Health, China CDC

Phase IV

December 2018

DGVTRU: Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection

NCT02656511

UCSF

Phase IV

January 2018

DIORR: Dolutegravir Impact on Residual Replication

NCT02500446

University of Melbourne

Phase IV

December 2016

DRONE: Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients

NCT02370979

University Hospital, Strasbourg, France

Phase IV

July 2017

AAHIV: antiretroviral therapy for acute HIV infection

NCT00796263

South East Asia Research Collaboration with Hawaii

Phase III

July 2019

VIRECURE: Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection

NCT02588820

David Garcia Cinca, Hospital Clinic of Barcelona

Phase III

May 2017

EIT: Early Infant HIV Treatment in Botswana

NCT02369406

Harvard School of Public Health

Phase II/III

February 2019

Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection

NCT02614950

South East Asia Research Collaboration with Hawaii

Phase II

October 2016

peginterferon alfa-2b

NCT02227277

The Wistar Institute

Phase II

January 2018

peginterferon alfa-2b

NCT01935089
(closed to enrollment)

University of Pennsylvania/Wistar Institute

Phase II

July 2016

alpha interferon intensification

NCT01295515
(closed to enrollment)

NIAID

Phase I/II

January 2020

IMPAACT P1115: Very early intensive treatment of HIV-infected infants to achieve HIV remission

NCT02140255

IMPAACT/NIAID/NICHD

Phase I/II

April 2022

 

Table 2. Observational Studies

Trial

Trial Registry Identifier(s)

Manufacturer/
Sponsor(s)

Phase

Estimated Study Completion Date

ACTG A5321: Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study

Not listed yet, see ACTG website entry for information

AIDS Clinical Trials Group

N/A

N/A

Analytic Treatment Interruption (ATI) to Assess HIV Cure

NCT02437526
(enrolling by invitation only)

Mayo Clinic

N/A

May 2020

CLEAC: Comparison of late versus early antiretroviral therapy in HIV-infected children

NCT02674867
(not yet open for enrollment)

French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)

N/A

December 2018

CODEX (the Extreme cohort)

NCT01520844

French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)

N/A

February 2018

Effects of Dolutegravir based regimen on HIV-1 reservoir and immune activation

NCT02557997

University Hospital, Strasbourg, France

N/A

September 2016

EPIC4: Early Pediatric Initiation: Canada Child cure Cohort Study

CTN S 281

Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS)

N/A

December 2018

Establish and characterize an acute HIV infection cohort in a high-risk population

NCT00796146

Southeast Asia Research Collaboration with Hawaii/Armed Forces Research Institute of Medical Sciences/Thai Red Cross AIDS Research Centre

N/A

July 2019

HEATHER: HIV Reservoir targeting with Early Antiretroviral Therapy

UK CPMS17589

University of Oxford/Medical Research Council/British HIV Association

N/A

September 2019

HIV-STAR: HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir

NCT02641756
(enrolling by invitation only)

University Hospital, Ghent

 

N/A

December 2019

Host & viral factors associated with HIV elite control

UK CPMS16146

University College London Hospitals NHS Foundation Trust

N/A

May 2021

HSCT-HIV: Allogeneic hematopoietic stem cell transplantation in HIV-1 infected patients

NCT02732457

Kirby Institute

N/A

September 2019

Impact of ART adherence on HIV persistence and inflammation

NCT02797093

University of Colorado, Denver

N/A

September 2017

ISALA: Analytical treatment interruption in HIV positive patients

NCT02590354

Institute of Tropical Medicine, Belgium

N/A

November 2017

Post analytic treatment interruption study

NCT02761200
(closed to enrollment)

South East Asia Research Collaboration with Hawaii

N/A

June 2020

Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans

NCT02154035

NIAID

N/A

December 2019

The use of leukapheresis to support HIV pathogenesis studies

NCT01161199

University of California, San Francisco

N/A

July 2020

Tat protein vaccine (roll-over observational study for extended follow-up of volunteers in the ISS T-003 trial)

NCT02712489
(closed to enrollment)

Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs

N/A

September 2016

 

Table 3. Completed Studies

Trial

Trial Registry Identifier(s)

Manufacturer/
Sponsor(s)

Phase

Published/Presented Data

ANTIBODIES

VRC01

NCT02463227

NIAID

Phase I

CROI 2016, Abstract 32LB, Webcast

3BNC117

NCT02018510

Rockefeller University

Phase I

Nature. 2015 Jun 25;522(7557):487-91

VRC01

NCT01950325

NIAID

Phase I

Sci Transl Med. 2015 Dec 23;7(319):319ra206

ANTI-FIBROTIC

ACE inhibitors

NCT01535235

UCSF/amfAR

Phase IV

N/A

ANTIRETROVIRAL THERAPY

raltegravir or efavirenz + tenofovir + emtricitibine

NCT00734344

University of Alabama at Birmingham

Phase IV

N/A

ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS

raltegravir + tenofovir + emtricitabine

NCT01025427

University of California, San Francisco

Phase IV

PLoS Pathog. 2013;9(10):e1003691

ASSEMBLY INHIBITOR

BIT225

ACTRN12612000696897

Biotron Limited

Phase I

J Antimicrob Chemother. 2016 Mar;71(3):731-8

COMBINATIONS

chemotherapy + maraviroc in people with non-Hodgkin lymphoma

NCT02486510

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 0

Terminated due to futility criteria

ERAMUNE-01
(antiretroviral intensification +/- interleukin-7)

NCT01019551

ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer

Phase II

AIDS. 2016 Jan;30(2):221-30

ERAMUNE-02

(DNA/Ad5 vaccine, ART intensification)

NCT00976404
 

Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS

Phase II

CROI 2014, Poster abstract 422

Vacc-4x + romidepsin

NCT02092116

Bionor Immuno AS/Celgene

Phase I/II

Lancet HIV 2016, Published Online July 7, 2016

Vacc-4x (peptide-based therapeutic vaccine) +
lenalidomide

NCT01704781

Bionor Immuno AS

Phase I/II

IAS 2015 Towards an HIV Cure Symposium, Poster Abstract PE61

vorinostat + hydroxychloroquine + maraviroc (VHM)

NCT02475915
NCT02470351 (CNS substudy)

South East Asia Research Collaboration with Hawaii

Phase I/II

AIDS 2016, Abstract TUAX0101LB

MVA-B (viral vector vaccine) +/- disulfiram

NCT01571466

Hospital Clinic of Barcelona/HIVACAT

Phase I

J Antimicrob Chemother. 2015 Feb 26. pii: dkv046.
PLoS One. 2015 Nov 6;10(11):e0141456.

GENE THERAPIES

SB-728-T

NCT01252641

Sangamo BioSciences

Phase I/II

 N/A

SB-728-T

NCT01044654

Sangamo BioSciences

Phase I

ICAAC 2014, Abstract H-643; 2013, Abstract H-1464c

SB-728-T
 

NCT00842634

Sangamo Biosciences/University of Pennsylvania

Phase I

N Engl J Med. 2014 Mar 6;370(10):901–10

Redirected high affinity Gag-specific T cells

NCT00991224

University of Pennsylvania/Adaptimmune

Phase I

N/A

HGTV43

No clinicaltrials.gov entry

Enzo Biochem

Phase I

AIDS 2006, Abstract MOPDA06

IMMUNE CHECKPOINT INHIBITORS

BMS-936559 (anti-PD-L1 antibody)

NCT02028403

National Institute of Allergy and Infectious Diseases (NIAID)

Phase I

N/A

IRON CHELATORS

deferiprone

NCT02456558
(closed to enrollment)

ApoPharma

Phase I

N/A

LATENCY-REVERSING AGENTS

bryostatin 1 (PKC agonist)

NCT02269605

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase I

AIDS. 2016 Feb 17. [Epub ahead of print]

disulfiram

NCT01286259

University of California, San Francisco/
Johns Hopkins University/amfAR

Not specified

Clin Infect Dis. 2014 58 (6): 88390

vorinostat (HDAC inhibitor)

NCT01365065

Bayside Health/Merck

Phase II

PLoS Pathog. 2014;10(10):e1004473

valproic acid (HDAC inhibitor)

NCT00289952

McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network

Phase II

HIV Med. 2012 May;13(5):291–6

valproic acid

NCT00614458

 

University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme Corp.

Phase II

 

PLoS One. 2010 5(2): e9390

disulfiram (acetaldehyde dehydrogenase inhibitor)

NCT01944371

University of California, San Francisco/Monash University/amfAR

Phase I/II

CROI 2015, Poster abstract 428LB

panobinostat (HDAC inhibitor)

NCT01680094

University of Aarhus/
Massachusetts General Hospital/
Monash University/Karolinska Institutet/
Novartis/amfAR

Phase I/II

The Lancet HIV. 2014 Oct; 1(1): e13–e21

CROI 2015, Abstract 109, Webcast

vorinostat

NCT01319383

University of North Carolina at Chapel Hill/NIAID/Merck

Phase I/II

Nature. 2012 Jul 25;487(7408):482-5
J Infect Dis. 2014 Sep 1;210(5):728-35

OBSERVATIONAL STUDIES

ANRS EP 44: Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)

NCT01038401

French National Agency for Research on AIDS and Viral Hepatitis

N/A

N/A

CHERUB 003
(prospective HIV chemotherapy cohort study)

NCT01902693

Imperial College London/CHERUB

N/A

N/A

 

HIV resistance and treatment strategies

NCT00581802

NIAID

N/A

N/A

In vitro autologous vaccine development to activate HIV reservoirs

UK CPMS17532

Imperial College London/amfAR

N/A

N/A

MUCOVIR: Exploration of HIV reservoirs

NCT01019044

Objectif Recherche Vaccins SIDA

N/A

JAIDS. 2013 Mar 1;62(3):255–9

Size of the HIV-1 reservoir and ongoing replication in defined cohorts

UK CPMS16004

University College London/amfAR

N/A

N/A

Tissue drug levels of HIV medications

NCT01490346

University of Minnesota – Clinical and Translational Science Institute/NIAID

N/A

Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.

ULTRASTOP (Towards HIV Functional Cure) ERAMUNE-03 (antiretroviral treatment interruption)

NCT01876862

Objectif Recherche VACcin Sida (ORVACS)/Fondation Bettencourt Schueller

N/A

AIDS, Published Ahead-of-Print, January 4, 2016

VIRECT: Impact of Pre-ART CD4 T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men

NCT02526940

Centre Hospitalier Universitaire de Saint Etienne

N/A

N/A

THERAPEUTIC VACCINES

AGS-004 (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)

NCT00672191

Argos Therapeutics

Phase IIb

J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8

AGS-004

NCT01069809

Argos Therapeutics

Phase IIb

IAS 2015 Towards an HIV Cure Symposium, Combination Therapy Trials Roundtable

DermaVir (topically applied DNA vaccine)

NCT00711230

Genetic Immunity

Phase II

N/A

DermaVir

NCT00918840

Genetic Immunity

Phase II

 

N/A

GSK Biologicals HIV Vaccine 732462 (p24-RT-Nef-p17 fusion protein vaccine)

NCT01218113

GlaxoSmithKline

Phase II

N/A

Tat protein vaccine

NCT01513135

Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development

Phase II

N/A

Tat protein vaccine

NCT01513135

Barbara Ensoli, MD, Istituto Superiore di Sanità

Phase II

Retrovirology. 2015 Apr 29;12(1):33
PLoS One. 2010 Nov 11;5(11):e13540

Vacc-4x (peptide-based vaccine)

NCT00659789

Bionor Immuno AS

Phase II

Lancet Infect Dis. 2014 Apr;14(4):291-300

VAC-3S (peptide-based vaccine)

NCT01549119

InnaVirVax

Phase I/IIa

30 Years of HIV Science, 2013, poster abstract 145
IAS 2015 Towards an HIV Cure Symposium, Poster Abstract PE67 LB

Dendritic cells pulsed with chemically inactivated HIV

NCT02766049

University of Sao Paulo General Hospital

Phase I/II

J Int AIDS Soc. 2014 Jan 10;17:18938
J. Cellular Immunotherapy xx (2016) 1-10

Dendritic cell vaccine

NCT00833781

Massachusetts General Hospital

Phase I/II

N/A

Autologous HIV-1 ApB DC Vaccine

NCT00510497

Sharon Riddler, University of Pittsburgh/NIAID

Phase I/II

N/A

Dendritic Cell Vaccine (DCV-2)

NCT00402142

Hospital Clinic of Barcelona

Phase I/II

Sci Transl Med. 2013 Jan 2;5(166):166ra2

DermaVir

NCT00270205

AIDS Clinical Trials Group

Phase I/II

JAIDS. 2013 Dec 1;64(4):3519

TUTI-16 (synthetic HIV-1 Tat epitope vaccine)

NCT01335191

Thymon, LLC

Phase I/II

Hum Vaccin Immunother. 2012 Oct;8(10):1425-30

Vacc-C5 (peptide-based vaccine)

NCT01627678

Bionor Immuno AS

Phase I/II

N/A

ChAdV63.HIVcons + MVA.HIVconsv (viral vector vaccines)

NCT01712425

IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford

Phase I

IAS 2015, Poster abstract MOPEA036

MVA.HIVconsv

NCT01024842

University of Oxford/Medical Research Council

Phase I

N/A

D-GPE DNA + M-GPE MVA (DNA + viral vector vaccines)

NCT01881581

Centers for Disease Control and Prevention, China

Phase I

N/A

JS7 DNA + MVA62B (DNA + viral vector vaccines)

NCT01378156

GeoVax, Inc.

Phase I

HIV R4P 2014, Abstract OA05.03 (webcast)

MAG pDNA vaccine +/- IL-12

NCT01266616

NIAID

Phase I

N/A

AT20-KLH

MED-AT20-001

Medestea Research & Production SpA, Turin

Phase I

Vaccine. 2014 Feb 19;32(9):1072-8

AFO-18 (peptide-based vaccine)

NCT01141205

Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP)

Phase I

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12

AFO-18 (peptide-based vaccine)

NCT01009762

SSI/Rigshospitalet/Hvidovre University Hospital/Ministry of the Interior and Health, Denmark

Phase I

Clin Immunol. 2013 Feb;146(2):120-30

Dendritic cells loaded with HIV-1 lipopeptides

NCT00796770

Baylor Research Institute/ANRS

Phase I

Retrovirology 2012, 9(Suppl 2):P328

DermaVir

NCT00712530

Genetic Immunity

Phase I

PLoS One. 2012 7(5): e35416

HIV-v (peptide-based vaccine)

NCT01071031

PepTcell Limited

Phase I

Vaccine. 2013 Nov 19;31(48):5680–6

PENNVAX-B (Gag, Pol, Env) + electroporation

NCT01082692

Inovio Pharmaceuticals

Phase I

Retrovirology 2012, 9(Suppl 2):P276

PENNVAX-B +/- IL-12 or IL-15

NCT00775424

University of Pennsylvania

Phase I

N/A

TREATMENT INTENSIFICATION/EARLY TREATMENT

Anti-HIV medications for people recently infected with HIV

NCT00106171

NIAID

Phase IV

PLoS One. 2015 10(11):e0143259

enfuvirtide

NCT00051831

NIAID

Not listed

J Infect Dis. 2010 Jan 15;201(2):2936

enfuvirtide 

NCT00334022

Canadian Immunodeficiency Research Collaborative

Not listed

N/A

PLUS: Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut

NCT00884793

University of California, San Francisco

Not listed

J Infect Dis. 2010 Nov 15;202(10):155361

AIDS. 2010 Oct 23;24(16):245160

ANRS 147 OPTIPRIM: Optimization of primary HIV-1 infection treatment

NCT01033760

French National Institute for Health and Medical ResearchFrench National Agency for Research on AIDS and Viral Hepatitis (InsermANRS)

Phase III

PLoS One. 2013; 8(5): e64219.

PLoS One. 2013; 8(3): e59767

IAS 2013, Abstract WEAB0101

IAS Cure Symposium, Presentation

maraviroc

NCT00808002

Germans Trias i Pujol Hospital

Phase III

AIDS. 2014 Jan 28;28(3):32534

raltegravir + maraviroc

NCT00935480

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Phase III

N/A

raltegravir

NCT00554398

Germans Trias i Pujol Hospital

Phase III

Antivir Ther. 2012;17(2):35564

Intense acute infection study

NCT01154673

University of Toronto

Phase II/III

N/A

maraviroc

NCT00795444

Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer

Phase II

PLoS One. 2011; 6(12):e27864

AIDS. 2013 Aug 24; 27(13):2081-8.

raltegravir

NCT00520897

Canadian Immunodeficiency Research Collaborative

Phase II

AIDS. 2012 Jan 14;26(2):167–74

raltegravir

NCT00807443

Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal

Phase II

AIDS. 2012 Sep 24;26(15):1885–94

indinavir + zidovudine + lamivudine + nevirapine

NCT00001644

NIAID

Phase I

N/A